Determination of bone-sialoprotein in bodily fluids for oncological problems
    1.
    发明授权
    Determination of bone-sialoprotein in bodily fluids for oncological problems 有权
    测定体液中骨涎蛋白的肿瘤学问题

    公开(公告)号:US07790853B2

    公开(公告)日:2010-09-07

    申请号:US10480441

    申请日:2002-06-06

    摘要: The invention relates to antibodies or a plurality of antibodies against human bone sialoprotein (BSP), characterized in that the antibodies bind to epitopes which are present only in human bone sialoprotein from tumor cells, the post-translational glycosylation of which is modified or incomplete in the region of amino acids of 120 to 135, containing the amino acids TGLAA (SEQ ID NO: 2), in comparison with normal bone sialoprotein from bones. The antibodies are put to use in an immunoassay for the diagnosis and prognosis of tumor diseases, in particular the diagnosis and prognosis of bone metastases in the case of primary breast carcinoma.

    摘要翻译: 本发明涉及针对人骨涎蛋白(BSP)的抗体或多种抗体,其特征在于所述抗体结合仅存在于来自肿瘤细胞的人骨涎蛋白的表位,其翻译后糖基化被修饰或不完全 与来自骨骼的正常骨涎蛋白相比,含有氨基酸TGLAA(SEQ ID NO:2)的氨基酸的区域为120至135。 在免疫测定中使用抗体用于肿瘤疾病的诊断和预后,特别是在原发性乳腺癌的情况下的骨转移的诊断和预后。